vs
MESA LABORATORIES INC（MLAB）与花花公子（PLBY）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是花花公子的1.9倍（$65.1M vs $34.9M），花花公子净利率更高（10.3% vs 5.6%，领先4.7%），花花公子同比增速更快（4.2% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $1.1M），过去两年花花公子的营收复合增速更高（11.0% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
花花公子集团（Playboy, Inc.）起源于1953年由休·海夫纳联合合伙人在美国芝加哥创立，初始部分资金来自海夫纳母亲提供的1000美元贷款，是美国知名生活方式与娱乐内容品牌，旗下核心《花花公子》杂志同时发行电子版与纸质版。
MLAB vs PLBY — 直观对比
营收规模更大
MLAB
是对方的1.9倍
$34.9M
营收增速更快
PLBY
高出0.6%
3.6%
净利率更高
PLBY
高出4.7%
5.6%
自由现金流更多
MLAB
多$16.9M
$1.1M
两年增速更快
PLBY
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $34.9M |
| 净利润 | $3.6M | $3.6M |
| 毛利率 | 64.2% | 73.3% |
| 营业利润率 | 12.2% | 7.9% |
| 净利率 | 5.6% | 10.3% |
| 营收同比 | 3.6% | 4.2% |
| 净利润同比 | 316.6% | 128.6% |
| 每股收益（稀释后） | $0.65 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABPLBY
| Q4 25 | $65.1M | $34.9M | ||
| Q3 25 | $60.7M | $29.0M | ||
| Q2 25 | $59.5M | $28.1M | ||
| Q1 25 | $62.1M | $28.9M | ||
| Q4 24 | $62.8M | $33.5M | ||
| Q3 24 | $57.8M | $29.4M | ||
| Q2 24 | $58.2M | $24.9M | ||
| Q1 24 | $58.9M | $28.3M |
净利润MLABPLBY
| Q4 25 | $3.6M | $3.6M | ||
| Q3 25 | $2.5M | $460.0K | ||
| Q2 25 | $4.7M | $-7.7M | ||
| Q1 25 | $-7.1M | $-9.0M | ||
| Q4 24 | $-1.7M | $-12.5M | ||
| Q3 24 | $3.4M | $-33.8M | ||
| Q2 24 | $3.4M | $-16.7M | ||
| Q1 24 | $-254.6M | $-16.4M |
毛利率MLABPLBY
| Q4 25 | 64.2% | 73.3% | ||
| Q3 25 | 61.5% | 76.0% | ||
| Q2 25 | 62.0% | 65.4% | ||
| Q1 25 | 61.8% | 68.6% | ||
| Q4 24 | 63.3% | 70.8% | ||
| Q3 24 | 61.3% | 61.0% | ||
| Q2 24 | 64.0% | 67.8% | ||
| Q1 24 | 62.1% | 55.8% |
营业利润率MLABPLBY
| Q4 25 | 12.2% | 7.9% | ||
| Q3 25 | 7.8% | 4.7% | ||
| Q2 25 | 5.1% | -20.9% | ||
| Q1 25 | 2.4% | -21.7% | ||
| Q4 24 | 9.2% | -13.3% | ||
| Q3 24 | 6.1% | -96.0% | ||
| Q2 24 | 9.6% | -37.0% | ||
| Q1 24 | -460.6% | -31.5% |
净利率MLABPLBY
| Q4 25 | 5.6% | 10.3% | ||
| Q3 25 | 4.1% | 1.6% | ||
| Q2 25 | 8.0% | -27.3% | ||
| Q1 25 | -11.4% | -31.3% | ||
| Q4 24 | -2.7% | -37.4% | ||
| Q3 24 | 5.9% | -114.7% | ||
| Q2 24 | 5.8% | -66.9% | ||
| Q1 24 | -432.2% | -58.1% |
每股收益（稀释后）MLABPLBY
| Q4 25 | $0.65 | $0.05 | ||
| Q3 25 | $0.45 | $0.00 | ||
| Q2 25 | $0.85 | $-0.08 | ||
| Q1 25 | $-1.30 | $-0.10 | ||
| Q4 24 | $-0.31 | $-0.13 | ||
| Q3 24 | $0.63 | $-0.45 | ||
| Q2 24 | $0.62 | $-0.23 | ||
| Q1 24 | $-47.26 | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $37.8M |
| 总债务越低越好 | $68.4M | $174.2M |
| 股东权益账面价值 | $186.7M | $18.4M |
| 总资产 | $434.8M | $292.4M |
| 负债/权益比越低杠杆越低 | 0.37× | 9.48× |
8季度趋势，按日历期对齐
现金及短期投资MLABPLBY
| Q4 25 | $29.0M | $37.8M | ||
| Q3 25 | $20.4M | $27.5M | ||
| Q2 25 | $21.3M | $19.6M | ||
| Q1 25 | $27.3M | $23.7M | ||
| Q4 24 | $27.3M | $30.9M | ||
| Q3 24 | $24.3M | $9.5M | ||
| Q2 24 | $28.5M | $16.9M | ||
| Q1 24 | $28.2M | $19.0M |
总债务MLABPLBY
| Q4 25 | $68.4M | $174.2M | ||
| Q3 25 | $69.4M | $176.8M | ||
| Q2 25 | $70.3M | $177.5M | ||
| Q1 25 | $71.3M | $176.3M | ||
| Q4 24 | $72.2M | $176.6M | ||
| Q3 24 | $73.1M | $200.0M | ||
| Q2 24 | $74.1M | $196.3M | ||
| Q1 24 | — | $193.4M |
股东权益MLABPLBY
| Q4 25 | $186.7M | $18.4M | ||
| Q3 25 | $178.5M | $3.8M | ||
| Q2 25 | $172.5M | $-17.5M | ||
| Q1 25 | $159.8M | $-11.4M | ||
| Q4 24 | $155.2M | $-7.7M | ||
| Q3 24 | $161.5M | $-15.7M | ||
| Q2 24 | $150.7M | $15.7M | ||
| Q1 24 | $145.4M | $29.5M |
总资产MLABPLBY
| Q4 25 | $434.8M | $292.4M | ||
| Q3 25 | $430.4M | $278.3M | ||
| Q2 25 | $435.7M | $264.1M | ||
| Q1 25 | $433.3M | $270.6M | ||
| Q4 24 | $433.3M | $284.7M | ||
| Q3 24 | $454.1M | $271.5M | ||
| Q2 24 | $440.4M | $301.8M | ||
| Q1 24 | $446.8M | $309.1M |
负债/权益比MLABPLBY
| Q4 25 | 0.37× | 9.48× | ||
| Q3 25 | 0.39× | 46.86× | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | 12.51× | ||
| Q1 24 | — | 6.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $1.4M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $1.1M |
| 自由现金流率自由现金流/营收 | 27.7% | 3.2% |
| 资本支出强度资本支出/营收 | 1.1% | 0.8% |
| 现金转化率经营现金流/净利润 | 5.17× | 0.39× |
| 过去12个月自由现金流最近4个季度 | $37.9M | $-1.0M |
8季度趋势，按日历期对齐
经营现金流MLABPLBY
| Q4 25 | $18.8M | $1.4M | ||
| Q3 25 | $8.2M | $10.1M | ||
| Q2 25 | $1.9M | $-3.9M | ||
| Q1 25 | $12.7M | $-7.6M | ||
| Q4 24 | $18.1M | $161.0K | ||
| Q3 24 | $5.3M | $-6.5M | ||
| Q2 24 | $10.7M | $-3.0M | ||
| Q1 24 | $12.9M | $-9.8M |
自由现金流MLABPLBY
| Q4 25 | $18.0M | $1.1M | ||
| Q3 25 | $7.1M | $9.8M | ||
| Q2 25 | $884.0K | $-4.3M | ||
| Q1 25 | $11.9M | $-7.7M | ||
| Q4 24 | $17.3M | $-401.0K | ||
| Q3 24 | $3.5M | $-7.0M | ||
| Q2 24 | $9.9M | $-3.7M | ||
| Q1 24 | $12.3M | $-10.3M |
自由现金流率MLABPLBY
| Q4 25 | 27.7% | 3.2% | ||
| Q3 25 | 11.7% | 33.8% | ||
| Q2 25 | 1.5% | -15.2% | ||
| Q1 25 | 19.2% | -26.5% | ||
| Q4 24 | 27.6% | -1.2% | ||
| Q3 24 | 6.0% | -23.7% | ||
| Q2 24 | 16.9% | -14.8% | ||
| Q1 24 | 21.0% | -36.5% |
资本支出强度MLABPLBY
| Q4 25 | 1.1% | 0.8% | ||
| Q3 25 | 1.8% | 1.1% | ||
| Q2 25 | 1.7% | 1.4% | ||
| Q1 25 | 1.2% | 0.1% | ||
| Q4 24 | 1.3% | 1.7% | ||
| Q3 24 | 3.1% | 1.5% | ||
| Q2 24 | 1.5% | 2.6% | ||
| Q1 24 | 0.9% | 2.1% |
现金转化率MLABPLBY
| Q4 25 | 5.17× | 0.39× | ||
| Q3 25 | 3.32× | 22.02× | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
PLBY
| Transferred At Point In Time | $22.2M | 64% |
| Trademark Licensing | $6.5M | 19% |
| Related Party | $5.0M | 14% |
| Other | $1.1M | 3% |
